Cystic Fibrosis Weekly Update

Contents:

First Patients Dosed in Trial Testing MS1819-SD Plus PERT for CF-related Severe EPI, AzurRX Says
Regular Exercise Promotes Lung Health in CF by Lowering Adiponectin Levels, Study Suggests

First Patients Dosed in Trial Testing MS1819-SD Plus PERT for CF-related Severe EPI, AzurRX Says

Oct 18, 2019 07:00 am | Alejandra Viviescas PhD

AzurRx BioPharma has started dosing patients in a Phase 2 clinical trial assessing its investigational therapy MS1819-SD in combination with porcine enzyme replacement therapy (PERT) for people with cystic fibrosis (CF) who have severe exocrine pancreatic insufficiency (EPI). People with CF can develop EPI when mucus obstructs the ducts of the pancreas, which prevents digestive […]
The post First Patients Dosed in Trial Testing MS1819-SD Plus PERT for CF-related Severe EPI, AzurRX Says appeared first on Cystic Fibrosis News Today.

Regular Exercise Promotes Lung Health in CF by Lowering Adiponectin Levels, Study Suggests

Oct 17, 2019 07:00 am | Patricia Inacio, PhD

Regular exercise over the long term improves lung function in people with cystic fibrosis (CF) by lowering levels of a pro-inflammatory hormone called adiponectin, a new study suggests. Measuring the levels of adiponectin and another hormone known as leptin could also be useful in monitoring CF progression, the investigators added. Their research, “Adiponectin Expression Is […]
The post Regular Exercise Promotes Lung Health in CF by Lowering Adiponectin Levels, Study Suggests appeared first on Cystic Fibrosis News Today.